FILE:LH/LH-8K-20041201163035.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
Summary information of the Company dated November 30, 2004.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Thomas P. Mac Mahon Chairman and Chief Executive Officer
 
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third- party payors.  Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2003, and subsequent filings.
2
 
The Clinical Laboratory Testing Market - $40 billion Annually
Independent clinical lab share is $16 billion
Represents 2% to 3% of all health care spending
Influences /directs approximately 80% of health care spending
Rapidly evolving technology, emphasis on preventative medicine and aging of population are all driving growth
Has grown at a CAGR of between 5% and 6%
Source:    Company estimates, industry reports and 2003 revenue for LabCorp.
3
 
Profile of LabCorp
A leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America
Offers more than 4,400 routine and esoteric/genomic tests
Conducts testing on more than 350,000 specimens daily
Provides lab services to more than 220,000 physicians and other health care providers
Approximately 23,000 employees nationwide
4
 
Primary Testing Locations & PSCs
Primary LabCorp Testing Locations
Patient Service Centers
PR
AK
Corporate Headquarters
Burlington, NC
5
 
LabCorp's Investment and Performance Fundamentals
History of Strong Financial Performance
Significant Cash Generator
Industry leading EBITDA margins
Strong Balance Sheet
Investment Grade Credit Ratings
6
 
Net Sales
(in millions)
7
 
EBITDA Margin
8
 
EPS
9
 
Operating Cash Flow
(in millions)
10
 
To
lead
the industry in achieving long-term
growth and profitability
by strengthening our
nationwide core testing
business and expanding our
higher-growth, higher-value esoteric and genomic businesses.
LabCorp's Strategy
11
 
Strategic Focus Areas
Scientific
Leadership
Managed
Care
Customer
Retention
-Licensing/partnerships
-Cancer
-Specimen tracking
-Call center consolidation
-Report improvement
-Acquisitions
-Appropriate prices
-Reduce leakage
-Value of new lab tests
-Customer connectivity
12
 
Third Quarter Results
(in millions, except per share data)
9/30/03
9/30/04
+/(-)
Revenue
$752.0
$781.5
3.9%
EBITDA
$183.9
$200.8
9.2%
EBITDA Margin
24.5%
25.7%
120
bp
EPS
$0.58
$0.66
13.8%
Bad Debt % of Revenue
7.5%
6.25%
(125)
bp
13
(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 3rd quarter 2004 earnings release furnished on Form 8-K on October  21, 2004.
(2) Q3 03 results above exclude restructuring and other one-time charges relating to the Company's integration of its DIANON and Dynacare acquisitions.
 
Nine-Month Results
(in millions, except per share data)
9/30/03
9/30/04
+/(-)
Revenue
$2,207.9
$2,318.3
5.0%
EBITDA
$537.0
$602.8
12.3%
EBITDA Margin
24.3%
26.0%
170
bp
EPS
$1.67
$1.97
18.0%
Bad Debt % of Revenue
7.5%
6.4%
(110)
bp
14
(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 3rd quarter 2004 earnings release furnished on Form 8-K on October  21, 2004.
(2) YTD 03 results above exclude restructuring and other one-time charges relating to the Company's integration of its DIANON and Dynacare acquisitions.
 
Financial Performance
Price & Volumes:  Trends by Payor Type
Client (Physicians)
Patient
Third Party
(MC/MD/Insurance)
Managed Care
Capitated
Fee for service
Total
LabCorp Total
2002
PPA
$
Accessions
millions
26.27
119.93
31.87
9.28
44.79
30.45
$31.71
29.6
2.3
14.8
13.1
19.3
32.4
79.1
2003
PPA
$
millions
27.07
118.48
34.25
9.95
45.68
32.74
$33.43
31.7
2.5
18.1
12.9
22.7
35.6
87.9
Accessions
YTD 2004
PPA
$
millions
26.54
122.91
34.63
10.17
45.74
33.28
$33.69
24.8
1.9
14.1
9.8
18.2
28.0
68.8
Accessions
15
 
Financial Performance
Revenue Analysis by Business Area
YTD SEPT 2003
Revenue
% Accns
Accns
PPA
$Million
to  total
000
$
Genomic
Identity/Gene Probes
All Genomic
Other Esoteric
Histology
All Genomic/         
          
Esoteric
Core
Total
213.6
1,733.8
2.6%
123.21
114.4
328.0
188.4
148.4
664.8
1,543.1
2,207.9
2,628.0
4,631.8
4,615.7
1,619.0
10,596.5
55,451.4
66,047.9
4.0%
6.6%
7.0%
2.4%
16.0%
84.0%
100.0%
43.52
75.20
40.81
91.67
62.74
27.83
33.43
YTD SEPT 2004
Revenue
% Accns
Accns
$Million
to  total
000
221.7
1,888.4
2.8%
117.40
125.0
346.7
221.8
146.0
714.5
1,603.8
2,318.3
2,843.3
4,731.7
5,360.1
1,587.8
11,679.6
57,141.7
68,821.3
4.1%
6.9%
7.8%
2.3%
17.0%
83.0%
100.0%
43.96
73.27
41.38
91.96
61.17
28.07
33.69
PPA
$
(4.7%)
1.0%
(2.6%)
1.4%
0.3%
(2.5%)
0.9%
0.9%
04 vs 03
PPA
Incr/(Decr)
16
 
Free Cash Flow Investment Strategy
Acquisitions
$250 million stock repurchase program
Retain flexibility in utilizing remaining cash
17
 


